Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. (NASDAQ: CRMD) concerning potential violations of the federal securities laws.
On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026. Management noted that the transition from its current TDAPA for DefenCath was expected to significantly reduce institutional reimbursement levels and net pricing in the second half of 2026. As a result, CorMedix lowered its full year revenue guidance from $400M down to $300M - $320M. Following this news, CRMD’s stock price fell over 21% to open at $8.73 per share.
If you suffered a loss on your CorMedix Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





